Skip to Content
Merck
CN

47674

Fmoc-Gln(Trt)-OH

≥98.0% (HPLC), for peptide synthesis

Synonym(s):

Nα-Fmoc-Nδ-trityl-L-glutamine

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):
C39H34N2O5
CAS Number:
Molecular Weight:
610.70
UNSPSC Code:
12352209
eCl@ss:
32160406
PubChem Substance ID:
NACRES:
NA.26
Beilstein/REAXYS Number:
4343953
MDL number:
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist


Product Name

Fmoc-Gln(Trt)-OH, ≥98.0% (HPLC)

Quality Level

assay

≥98.0% (HPLC)

form

powder

optical activity

[α]/D -14.0±1.5°, c = 1% in DMF

reaction suitability

reaction type: Fmoc solid-phase peptide synthesis

application(s)

peptide synthesis

functional group

Fmoc

storage temp.

2-8°C

SMILES string

OC(=O)[C@H](CCC(=O)NC(c1ccccc1)(c2ccccc2)c3ccccc3)NC(=O)OCC4c5ccccc5-c6ccccc46

InChI

1S/C39H34N2O5/c42-36(41-39(27-14-4-1-5-15-27,28-16-6-2-7-17-28)29-18-8-3-9-19-29)25-24-35(37(43)44)40-38(45)46-26-34-32-22-12-10-20-30(32)31-21-11-13-23-33(31)34/h1-23,34-35H,24-26H2,(H,40,45)(H,41,42)(H,43,44)/t35-/m0/s1

InChI key

WDGICUODAOGOMO-DHUJRADRSA-N

General description

Fmoc-Gln(Trt)-OH also known as Nα-Fmoc-Nδ-trityl-L-glutamine, a Fmoc protected amino acid derivative used as a reagent in the synthesis of peptides. As glutamine is protected with a trityl group, unwanted substitute products in the reactions can be prevented.

Application

Fmoc-Gln(Trt)-OH is used as a starting material in the Fmoc solid phase peptide synthesis of fellutamide B and N-octanoyl analog of fellutamide B.


Still not finding the right product?

Explore all of our products under Fmoc-Gln(Trt)-OH


Storage Class

11 - Combustible Solids

wgk

WGK 1

ppe

Eyeshields, Gloves, type N95 (US)



Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library



Cathleen Jendrny et al.
Chembiochem : a European journal of chemical biology, 17(8), 719-726 (2015-11-18)
Serpin proteins irreversibly inhibit serine proteases, but only a small part of the serpin reactive-center loop (RCL) is responsible for the initial protein-protein interaction (PPI). To develop peptidic protease inhibitors, kallikrein-related peptidases 7 (KLK7) and 5 (KLK5) were chosen. Firstly
Marcus Pickhardt et al.
Current Alzheimer research, 14(7), 742-752 (2017-02-06)
Anti-aggregation drugs play an important role in therapeutic approaches for Alzheimer's disease. We have previously developed a number of compounds that are able to inhibit the pathological aggregation of Tau protein. One common obstacle to application is the limited penetration
Fatemeh Zabihi et al.
Journal of controlled release : official journal of the Controlled Release Society, 242, 35-41 (2016-07-30)
Nanogels offer many unique features rendering them as very attractive candidates for drug delivery. However, for their applications the loading capacity and specific encapsulation, in particular for hydrophobic drugs, in a complex media are two critical factors. In this work



Global Trade Item Number

SKUGTIN
47674-100G-F04061832372723
47674-1KG-F04061826222805
47674-25G-F04061832372730
47674-5G-F04061832372747